89bio to participate in the svb leerink 11ᵗʰ annual global healthcare conference

San francisco, feb. 09, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that company's management will participate in a fireside chat and one-on-one investor meetings at the svb leerink 11th annual global healthcare conference on wednesday, february 16, 2022 at 12:00 pm et.
ETNB Ratings Summary
ETNB Quant Ranking